ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+15.54% - 334,922 M€
+13.82% - 2,210 M€
+5.64% - 1,193 M€
+19.30% - 1,646 M€
-2.84%4.85% 5 M€
+18.73%4.05% 81 M€
+4.23%3.39% 94 M€
+13.94%1.83% 331 M€
+15.68%1.5% 210 M€
+8.70%1.29% 1,882 M€
+16.68%1.15% 19 M€
+7.91%1.12% 6,576 M€
+19.81%1.06% 122 M€
+13.96%1% 13 M€
+7.78%0.62% 8 M€
+6.53%0.54% 361 M€
+7.14%0.42% 8,285 M€
+5.07%0.31% 5,369 M€
+14.13%0.3% 630 M€
+22.31%0.3% 2,914 M€
-5.03%0.3% 15 M€
+20.81%0.3% 38 M€
+20.34%0.3% 100 M€
+13.96%0.3% 16 M€
+5.36%0.29% 40 M€
+18.48%0.29% 115 M€
+19.04%0.29% 138 M€
-0.45%0.28% 13,961 M€
+19.81%0.27% 6,226 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100